François Ravenelle, PhD

Director

President & CEO of Innospera Pharma and former President & CEO of Inversago Pharma, where he raised more than US$110 million and led the company through clinical development to its acquisition by Novo Nordisk for up to US$1.075 billion. Brings more than 20 years of experience advancing therapeutics from discovery through Phase 2, including contributing to an approved NDA.